一种二聚体FAP靶向小分子放射性偶联物具有高且持久的肿瘤摄取
本研究开发了二聚体FAP结合基序BiOncoFAP,并在小鼠体内与单体OncoFAP对比。177Lu-BiOncoFAP在注射后24小时肿瘤摄取约20%ID/g,显著高于177Lu-OncoFAP的约4%ID/g,且肿瘤/器官比值有利、肾脏摄取低。两者在治疗剂量下均显示有效抗肿瘤疗效。
要点
- 177Lu-BiOncoFAP在24小时肿瘤摄取约20%ID/g,高于177Lu-OncoFAP的约4%ID/g。
- BiOncoFAP与OncoFAP对人重组FAP的亲和力均为亚纳摩尔级,但BiOncoFAP对固相固定靶点结合更牢固。
- 177Lu-BiOncoFAP肿瘤/器官比值有利且肾脏摄取低,治疗剂量下两者均有有效抗肿瘤疗效。
核心结论
- 177Lu-BiOncoFAP是有前景的癌症放射配体治疗候选药物,具有有利的体内肿瘤/器官比值、长肿瘤滞留时间和有效抗癌疗效。
研究设计与样本
- 临床前研究:体外测定BiOncoFAP和OncoFAP对重组人FAP的结合特性,并在荷FAP阳性HT-1080肿瘤小鼠中进行177Lu-OncoFAP-DOTAGA和177Lu-BiOncoFAP-DOTAGA的体内表征。
主要发现
- OncoFAP和BiOncoFAP对溶液中重组人FAP的解离常数均为亚纳摩尔级且相当,但二价BiOncoFAP对固相载体固定的靶点结合更牢固。
- 在对比生物分布研究中,注射后24小时177Lu-BiOncoFAP肿瘤摄取约20%ID/g,177Lu-OncoFAP约4%ID/g,前者更稳定持久。
- 177Lu-BiOncoFAP显示有利的肿瘤/器官比值,肾脏摄取低。
- 在荷瘤小鼠中给予治疗剂量时,177Lu-OncoFAP和177Lu-BiOncoFAP均显示有效抗肿瘤疗效。
关键数值与推荐
- 177Lu-BiOncoFAP注射后24小时肿瘤摄取约20%ID/g,177Lu-OncoFAP约4%ID/g。
- OncoFAP和BiOncoFAP对重组人FAP的解离常数均为亚纳摩尔级。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Imaging procedures based on small-molecule radioconjugates targeting fibroblast activation protein (FAP) have recently emerged as a powerful tool for the diagnosis of a wide variety of tumors. However, the therapeutic potential of radiolabeled FAP-targeting agents is limited by their short residence time in neoplastic lesions. In this work, we present the development and in vivo characterization of BiOncoFAP, a new dimeric FAP-binding motif with an extended tumor residence time and favorable tumor-to-organ ratio. Methods: The binding properties of BiOncoFAP and its monovalent OncoFAP analog were assayed against recombinant human FAP. Preclinical experiments with 177Lu-OncoFAP-DOTAGA (177Lu-OncoFAP) and 177Lu-BiOncoFAP-DOTAGA (177Lu-BiOncoFAP) were performed on mice bearing FAP-positive HT-1080 tumors. Results: OncoFAP and BiOncoFAP displayed comparable subnanomolar dissociation constants toward recombinant human FAP in solution, but the bivalent BiOncoFAP bound more avidly to the target immobilized on solid supports. In a comparative biodistribution study, 177Lu-BiOncoFAP exhibited a more stable and prolonged tumor uptake than 177Lu-OncoFAP (∼20 vs. ∼4 percentage injected dose/g, respectively, at 24 h after injection). Notably, 177Lu-BiOncoFAP showed favorable tumor-to-organ ratios with low kidney uptake. Both 177Lu-OncoFAP and 177Lu-BiOncoFAP displayed potent antitumor efficacy when administered at therapeutic doses to tumor-bearing mice. Conclusion: 177Lu-BiOncoFAP is a promising candidate for radioligand therapy of cancer, with favorable in vivo tumor-to-organ ratios, a long tumor residence time, and potent anticancer efficacy.
引用
- Galbiati A, Zana A, Bocci M, et al. A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake. J Nucl Med. 2022. PMID: 35589404. doi:10.2967/jnumed.122.264036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。